Two Sigma Investments LP Takes $606,000 Position in Quanterix Co. (NASDAQ:QTRX)

Two Sigma Investments LP bought a new stake in Quanterix Co. (NASDAQ:QTRX) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 56,962 shares of the company’s stock, valued at approximately $606,000. Two Sigma Investments LP owned about 0.15% of Quanterix at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Resona Asset Management Co. Ltd. bought a new position in shares of Quanterix in the 4th quarter valued at about $55,000. Tower Research Capital LLC TRC boosted its stake in shares of Quanterix by 219.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 5,702 shares of the company’s stock valued at $61,000 after purchasing an additional 3,915 shares during the last quarter. KLP Kapitalforvaltning AS bought a new position in shares of Quanterix in the 4th quarter valued at about $66,000. Canada Pension Plan Investment Board boosted its stake in shares of Quanterix by 64.5% in the 4th quarter. Canada Pension Plan Investment Board now owns 10,200 shares of the company’s stock valued at $108,000 after purchasing an additional 4,000 shares during the last quarter. Finally, ProShare Advisors LLC bought a new position in Quanterix during the 4th quarter worth approximately $108,000. Institutional investors own 86.48% of the company’s stock.

Quanterix Stock Performance

Shares of QTRX opened at $5.37 on Monday. Quanterix Co. has a twelve month low of $4.05 and a twelve month high of $19.18. The firm’s 50 day moving average price is $5.31 and its two-hundred day moving average price is $7.92. The firm has a market cap of $208.51 million, a P/E ratio of -5.07 and a beta of 1.05.

Quanterix (NASDAQ:QTRX) last posted its quarterly earnings data on Monday, May 12th. The company reported ($0.53) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.16. Quanterix had a negative net margin of 30.12% and a negative return on equity of 11.74%. The company had revenue of $30.33 million for the quarter, compared to the consensus estimate of $28.27 million. On average, sell-side analysts anticipate that Quanterix Co. will post -0.98 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the stock. Leerink Partnrs lowered shares of Quanterix from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 30th. Scotiabank reissued an “outperform” rating on shares of Quanterix in a research note on Tuesday, March 25th. Canaccord Genuity Group reduced their price objective on shares of Quanterix from $15.00 to $12.00 and set a “buy” rating on the stock in a research note on Tuesday, May 13th. Leerink Partners reissued a “market perform” rating and set a $8.00 price objective (down previously from $12.00) on shares of Quanterix in a research note on Wednesday, April 30th. Finally, Wall Street Zen lowered shares of Quanterix from a “hold” rating to a “sell” rating in a research note on Thursday, May 22nd. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $15.60.

About Quanterix

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.